Sun Pharma Stock: FY26 Revenue at Rs 58,462 Crore as Organon Acquisition Plan Emerges

What Sun Pharma's FY26 Results and Organon Plan Changed

Sun Pharma reported full year FY26 revenue of Rs 58,462 crore and profit of Rs 11,479 crore, and disclosed plans to pursue an acquisition involving Organon, the women's health and established-medicines company that was spun off from Merck a few years ago. Putting a specific target and specific full-year numbers together in one update gives readers two separate but related things to weigh: how the existing business performed, and where the company wants to expand next.

Why Sun Pharma Stock Is in Focus

The stock is in focus because Sun Pharma is India's largest drugmaker by market value, and both halves of this update matter to its story. The FY26 revenue and profit figures show the scale the company has already reached across its branded generics, US generics and specialty medicine businesses. An acquisition tied to Organon would be a different kind of move: Organon's portfolio is centred on women's health, biosimilars and older branded drugs that still generate steady cash flow, areas that could deepen Sun Pharma's specialty and international branded-drug presence rather than just adding more plain generic volume. Large acquisitions in pharma also carry integration risk and usually involve raising or deploying significant capital, so the eventual deal terms, if the plan proceeds, will matter as much as the announcement itself.

Which Stocks, and Why

Sun Pharma is the only company named here, so the impact is direct. As the sector's largest player, its results are often used as a reference point for how Indian pharma exporters are performing in the US and other overseas markets, but this specific combination of a large-scale results update and a large potential acquisition is a company-specific development rather than a signal about the wider pharma sector.

What to Watch

The most important things to track from here are whether the Organon-related transaction is actually finalised, at what valuation, and which specific assets or geographies it covers, since 'plans to acquire' is not the same as a signed deal. Readers should also watch how Sun Pharma's US and India formulation segments performed within the FY26 numbers when the full results breakdown is published, and any management commentary on how a deal of this size would be funded, whether through cash reserves, debt, or a mix of both.